source
- BMS terminates Cellares partnership after cell therapy platform fails to meet Breyanzi production needs, prompting layoffsBristol Myers Squibb has ended its collaboration with manufacturing specialist Cellares after the Cell Shuttle system could not satisfy the requirements for producing the approved CAR‑T therapy Bre…
- Biohaven signs up to $795 million deal with SK Biopharma to license Kv7 platform and epilepsy assetBiohaven announced a licensing agreement with South Korean SK Biopharma centered on its Kv7 ion channel platform and lead epilepsy candidate opakalim. The deal could deliver up to $795 million, in…